Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12118635 | 0.83 | DGAT1 (0.44) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL17675540 | 0.83 | DGAT1 (0.39) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL12118691 | 0.83 | DGAT1 (0.44) | DGAT1BRD4CREBBP | |
| SCHEMBL17675396 | 0.83 | DGAT1 (0.39) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL14435378 | 0.82 | DGAT1 (0.38) | DGAT1BRD4CREBBPPDE10A | |
| SCHEMBL24102662 | 0.81 | DGAT1 (0.38) | DGAT1BRD4CREBBPPDE10A | |
| SCHEMBL15694427 | 0.81 | DGAT1 (0.38) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL31631794 | 0.81 | DGAT1 (0.38) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL31629427 | 0.81 | DGAT1 (0.38) | DGAT1BRD4CREBBP | |
| SCHEMBL31631877 | 0.81 | DGAT1 (0.38) | DGAT1BRD4CREBBPPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4281182-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | Hibercell, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159746-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-3143021-B1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9518052-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | DGAT1 3940/4885FDPS 31/4885BRD4 963/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | DGAT1 3940/4885FDPS 31/4885BRD4 963/4885 |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | DGAT1 565/4885FDPS 1785/4885BRD4 2126/4885 |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | CBR3, HRH4, REN | DGAT1 4350/4885FDPS 1717/4885BRD4 22/4885 |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | DGAT1 3733/4885FDPS 1928/4885BRD4 202/4885 |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | DGAT1 3733/4885FDPS 1928/4885BRD4 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.